RecruitingPhase 1Phase 2NCT02813135

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Enrollment

472 participants

Start Date

Aug 3, 2016

Study Type

INTERVENTIONAL

Conditions

Pediatric Cancer

Summary

This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019). The aims of the trial are: 1. To determine the recommended phase II dose (RP2D) of a specific anticancer agent and/or a relevant combination in a pediatric population, to document its tolerability and 2. To explore first signals of activity in a molecularly enriched study population.

Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adavosertib, a drug called Avelumab, and others for people with pediatric cancer. The study is currently recruiting participants at 21 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRibociclib

DRUGTopotecan

DRUGTemozolomide

DRUGEverolimus

DRUGAdavosertib

DRUGCarboplatin

DRUGOlaparib

DRUGIrinotecan

DRUGVistusertib

DRUGNivolumab

DRUGCyclophosphamide

DRUGSelumetinib

DRUGEnasidenib

DRUGLirilumab

DRUGFadraciclib

DRUGCytarabine

DRUGDexamethasone

DRUGCeralasertib

DRUGFutibatinib

DRUGCapmatinib

DRUGAvelumab

DRUGPeposertib

DRUGCapivasertib

DRUGVinorelbine

Locations(23)

Rigshospitalet

Copenhagen, Denmark

Gustave Roussy

Villejuif, Val de Marne, France

CHU Angers

Angers, France

CHU Pellegrin

Bordeaux, France

Centre Oscar Lambret

Lille, France

Centre Léon Bérard

Lyon, France

Hôpital de La Timone

Marseille, France

CHU Nantes

Nantes, France

Institut Curie

Paris, France

Hôpital Armand Trousseau

Paris, France

Hôpital de Hautepierre

Strasbourg, France

Istituto Giannina Gaslini

Genova, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Italy

Ospedale Infantile Regina Margherita

Torino, Italy

Prinses Maxima Centrum

Utrecht, Netherlands

Vall d'Hebron

Barcelona, Spain

Hospital del Nino Jesus

Madrid, Spain

Hospital Universitario La Fe

Valencia, Spain

Birmingham Children's Hospital

Birmingham, United Kingdom

Great Ormond Street Hospital

London, United Kingdom

Royal Manchester Children's Hospital

Manchester, United Kingdom

Royal Victoria Infirmary

Newcastle, United Kingdom

Pediatric and Adolescent Oncology The Royal Marsden Hospital

Sutton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02813135

Related Trials

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

NCT064580365 locations

Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients

NCT049486191 location

LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients

NCT050585081 location

Psychological Benefits of a Normalized Camping Experience for Children With Cancer

NCT000011861 location

Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer

NCT052943023 locations